Five-Year Outcomes From KEYNOTE-024: Pembroli-zumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

LU Shun

doi:10.12019/j.issn.1671-5144.2021.04.002

LU Shun. Five-Year Outcomes From KEYNOTE-024: Pembroli-zumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 197-201. DOI: 10.12019/j.issn.1671-5144.2021.04.002

Citation:

LU Shun. Five-Year Outcomes From KEYNOTE-024: Pembroli-zumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 197-201. DOI: 10.12019/j.issn.1671-5144.2021.04.002

Citation:

LU Shun. Five-Year Outcomes From KEYNOTE-024: Pembroli-zumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 197-201. DOI: 10.12019/j.issn.1671-5144.2021.04.002

Five-Year Outcomes From KEYNOTE-024: Pembroli-zumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

LU Shun

Graphical Abstract

Abstract

FullText(HTML)

References (12)

Five-Year Outcomes From KEYNOTE-024: Pembroli-zumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Catalog

Export File

Citation

Format

Content